Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
QNCX on Nasdaq
Shares outstanding
56,260,480
Price per share
$3.35
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
11,792,663
Total reported value
$19,221,893
% of total 13F portfolios
0%
Share change
+4,213,876
Value change
+$6,863,066
Number of holders
45
Price from insider filings
$3.35
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 10% 0% $9,159,602 +$1,392,676 5,620,422 +18% Nantahala Capital Management, LLC 30 Sep 2025
Sofinnova Partners SAS 2.7% -54% $1,592,956 -$1,596,000 1,197,711 -50% Sofinnova Capital VIII 31 Mar 2025

As of 30 Sep 2025, 45 institutional investors reported holding 11,792,663 shares of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX). This represents 21% of the company’s total 56,260,480 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) together control 21% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Nantahala Capital Management, LLC 5.5% 3,073,729 +22% 0.31% $5,010,178
VANGUARD GROUP INC 3.1% 1,763,387 +21% 0% $2,874,320
MILLENNIUM MANAGEMENT LLC 2.5% 1,386,776 +1153% 0% $2,260,445
IEQ CAPITAL, LLC 1.7% 981,264 +123% 0% $1,599,460
ADAR1 Capital Management, LLC 1.4% 775,034 +442% 0.13% $1,263,305
Almitas Capital LLC 0.88% 494,778 0.18% $806,488
RENAISSANCE TECHNOLOGIES LLC 0.83% 468,598 +23% 0% $763,815
GEODE CAPITAL MANAGEMENT, LLC 0.78% 437,285 +10% 0% $712,910
BlackRock, Inc. 0.61% 345,461 +2.9% 0% $563,101
HighTower Advisors, LLC 0.55% 308,500 0% 0% $502,855
Union Square Park Capital Management, LLC 0.4% 224,746 +86% 0.25% $366,336
MARSHALL WACE, LLP 0.37% 210,045 0% $342,372
STATE STREET CORP 0.35% 198,111 +59% 0% $322,921
Alphabet Inc. 0.34% 189,122 0% 0.01% $308,269
Shay Capital LLC 0.24% 136,955 -8.7% 0.04% $223,237
Mariner, LLC 0.22% 122,461 0% 0% $199,611
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.17% 95,122 -26% 0% $155,049
SCHARF INVESTMENTS, LLC 0.16% 91,061 0% 0% $148,429
SIMPLEX TRADING, LLC 0.16% 88,519 0% $144,000
GSA CAPITAL PARTNERS LLP 0.16% 87,235 +158% 0.01% $142,000
NORTHERN TRUST CORP 0.12% 64,706 -16% 0% $105,471
CITADEL ADVISORS LLC 0.1% 56,914 -39% 0% $92,770
JANE STREET GROUP, LLC 0.06% 35,160 0% $57,311
Operose Advisors LLC 0.06% 31,568 0.01% $51,455
GROUP ONE TRADING LLC 0.05% 30,830 0% $50,253

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 91,061 $305,054 $3.35 1
2025 Q3 11,792,663 $19,221,893 +$6,863,066 $1.63 45
2025 Q2 7,578,787 $12,505,248 +$3,952,653 $1.65 40
2025 Q1 5,230,260 $6,956,589 +$1,241,118 $1.33 35
2024 Q4 5,108,209 $9,552,089 +$494,140 $1.87 33
2024 Q3 5,193,769 $4,039,786 -$768,365 $0.78 32
2024 Q2 6,237,289 $4,672,274 -$801,175 $0.75 40
2024 Q1 7,261,875 $7,696,374 -$188,697 $1.06 43
2023 Q4 10,148 $10,655 $1.05 1
2023 Q3 7,481,167 $8,378,992 -$2,281,475 $1.12 38
2023 Q2 8,954,348 $13,476,697 +$1,945,497 $1.50 36
2023 Q1 7,617,291 $11,882,062 +$3,799,109 $1.56 38
2022 Q4 5,356,256 $3,410,876 -$3,304,154 $0.64 44
2022 Q3 9,088,711 $12,084,077 -$3,518,480 $1.33 50
2022 Q2 11,022,447 $24,465,549 -$25,394,859 $2.22 57
2022 Q1 11,438,058 $70,790,251 -$28,034,053 $6.19 79
2021 Q4 16,610,815 $209,631,654 -$232,811,213 $12.62 90
2021 Q3 19,191,432 $1,759,089,977 +$81,258,026 $91.66 130
2021 Q2 18,535,832 $982,404,976 -$6,013,549 $53.00 104
2021 Q1 18,681,744 $673,084,454 +$37,640,446 $36.03 89
2020 Q4 17,656,872 $490,520,403 +$26,851,066 $27.78 84
2020 Q3 16,535,561 $826,596,550 +$55,394,377 $50.00 83
2020 Q2 15,442,461 $714,724,484 +$184,939,141 $46.30 81
2020 Q1 11,450,501 $522,757,976 +$39,593,801 $45.61 65
2019 Q4 10,587,998 $594,413,680 +$91,848,055 $56.14 50
2019 Q3 5,839,518 $144,771,494 +$81,538,555 $24.93 40
2019 Q2 2,419,629 $102,854,360 +$102,853,772 $42.51 36